Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22983Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Agouridis, A. P. | en |
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Derdemezis, C. S. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:29:37Z | - |
| dc.date.available | 2015-11-24T19:29:37Z | - |
| dc.identifier.issn | 1873-4286 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22983 | - |
| dc.rights | Default Licence | - |
| dc.subject | Animals | en |
| dc.subject | Drug Therapy, Combination | en |
| dc.subject | Fenofibrate/administration & dosage/*pharmacology/therapeutic use | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/therapeutic use | en |
| dc.subject | Hyperlipidemias/*drug therapy/physiopathology | en |
| dc.subject | Hypolipidemic Agents/administration & dosage/*pharmacology/therapeutic use | en |
| dc.subject | Lipid Metabolism/drug effects | en |
| dc.subject | Metabolic Syndrome X/drug therapy/etiology/physiopathology | en |
| dc.subject | Obesity/complications | en |
| dc.title | Combination of fenofibrate with non-statin drug regimens | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/20819059 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2010 | - |
| heal.abstract | OBJECTIVE: We present the available data on the effects of combined therapy of fenofibrate with drugs affecting lipid metabolism other than statins. METHODS: We consider studies evaluating the effects of combined therapy of fenofibrate with bile acid sequestrants (BAS), ezetimibe, niacin, n-3 fatty acids, plant sterols, orlistat, rimonabant, metformin and glitazones. RESULTS: Combination of BAS (especially colesevelam) with fenofibrate had additional effects on metabolic parameters in patients with mixed hyperlipidemia. Combination of ezetimibe with fenofibrate may be a useful approach to improve the overall lipid profile of patients with mixed hyperlipidemia. There is a further reduction in triglyceride levels when n-3 fatty acids are administered with fenofibrate in patients with severe hypertriglyceridemia. Combined fenofibrate and orlistat treatment further improves metabolic parameters in overweight/obese patients with metabolic syndrome. The fenofibrate/thiazolidinedione combination is an alternative for diabetic patients intolerant to statins, though differences exist between pioglitazone and rosiglitazone. CONCLUSIONS: For patients who cannot tolerate statins there are useful combinations of fenofibrate with other drugs affecting lipid metabolism. These combinations improve several metabolic parameters, but more trials should be carried out to reach more robust conclusions about their effects on cardiovascular events. | en |
| heal.journalName | Curr Pharm Des | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
